![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
MedImmune LLC |
---|---|
Information provided by: | MedImmune LLC |
ClinicalTrials.gov Identifier: | NCT00123942 |
The primary objective of this study is to determine the maximum tolerated dose (MTD) and safety and tolerability of MEDI-507 in patients with CD2-positive lymphoproliferative disorders.
Condition | Intervention | Phase |
---|---|---|
Lymphoproliferative Disorders |
Drug: MEDI-507 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | Phase I Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Histologically confirmed diagnosis of a lymphoproliferative disorder as determined by the Laboratory of Pathology at the Clinical Center at the National Institutes of Health (NIH). Only patients with the following lymphoproliferative disorders will be eligible:
LGL: Patients with large granular lymphocyte leukemia (LGL) must have myelosuppression (granulocyte count ≤1,500/uL; platelet count
Exclusion Criteria:
United States, Maryland | |
National Cancer Institute/National Institutes of Health | |
Bethesda, Maryland, United States, 20892 |
Principal Investigator: | John Janik, MD | National Cancer Institute (NCI) |
Study Director: | Karen Kaucic, MD | MedImmune LLC |
Study ID Numbers: | MI-CP099 |
Study First Received: | July 22, 2005 |
Last Updated: | June 12, 2007 |
ClinicalTrials.gov Identifier: | NCT00123942 History of Changes |
Health Authority: | United States: Food and Drug Administration |
CD2+ Lymphoproliferative disorder |
Lymphatic Diseases Immunoproliferative Disorders Lymphoproliferative Disorders |
Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoproliferative Disorders |